A three-agent neoadjuvant regimen that combines a PD-L1 inhibitor with chemotherapy appears feasible for patients with malignant pleural mesothelioma, according to an ongoing phase I trial. The findings [ about neoadjuvant therapy ] were presented at the International Association for the Study of Lung Cancer virtual World Conference on Lung Cancer, … [Read more...]
Nivo/Ipi Combo Now ‘Standard of Care’ in Mesothelioma
The [ combination immunotherapy consisting ] of nivolumab (Opdivo) and ipilimumab (Yervoy) offers a durable, long-term survival benefit over chemotherapy for patients with unresectable malignant pleural mesothelioma (MPM), confirms a 3-year updated analysis of the CheckMate 743 trial. After 3 years, 23% of patients who received combination … [Read more...]
Access to care varies greatly among patients with malignant pleural mesothelioma
Access to care varied significantly among patients with stage I to stage III malignant pleural mesothelioma, according to study results. The findings — presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer — showed variations in access based on factors such as distance to treatment facility, as well … [Read more...]
More Data in Support of Surgery for Malignant Pleural Mesothelioma
Patients with malignant pleural mesothelioma (MPM) lived 6 months longer, on average, when they had surgery in addition to chemotherapy, a large retrospective analysis showed. The addition of surgery to combination chemotherapy resulted in a median overall survival (OS) of 22 months as compared with 16 months with chemotherapy alone. Twice as … [Read more...]
Appeals court reinstates suit by Solano County woman against Johnson & Johnson over baby powder
A state appeals court reinstated a lawsuit Tuesday by the widow of a Solano County man who died of cancer after using [ Johnson & Johnson Baby Powder ] for most of his life. A judge had dismissed the suit by Douglas Strobel and his wife, Jo Ann Strobel, saying their medical witnesses had no firsthand evidence that the talcum in [ Johnson … [Read more...]
Understanding the new therapeutic options for mesothelioma
Since the US Food and Drug Administration (FDA) approved pemetrexed plus cisplatin for first-line treatment of mesothelioma in 2004, there has been a dearth of additional treatment options for this disease. Despite substantial effort, no other phase 3 study achieved a positive outcome for another 12 years, until the MAPS trial showed that the … [Read more...]
Surgery After Radiotherapy May Improve Outcomes in Patients with Malignant Pleural Mesothelioma
A particular surgery performed following the completion of radiotherapy treatment among a group of patients with malignant pleural mesothelioma was associated with improved outcomes including overall survival, according to study results recently published in Lancet Oncology. “Different treatment strategies have been tried (for malignant pleural … [Read more...]
Court upholds award to family of worker who died of asbestos exposure
The South Carolina Supreme Court [in August 2021] upheld a $16 million jury award to the family of a maintenance worker at a polyester fiber plant who died following years of asbestos exposure. Hystron Fibers Inc., owned by defendant CNA Holdings, hired Daniel Construction Co. in 1965 to build a plant in Spartanburg, South Carolina. When the … [Read more...]
Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma
Objectives: Second-line immune checkpoint inhibition (ICI) was recently shown to have a survival advantage over placebo in malignant pleural mesothelioma (MPM), but the survival comparison to chemotherapy in patients with MPM receiving routine clinical care is unknown. Our objective was to examine the effectiveness of second-line ICI versus … [Read more...]
Drug Combo Promising in Rare Mesothelioma
A combination of atezolizumab (Tecentriq) and bevacizumab appeared effective and safe in patients with advanced malignant peritoneal mesothelioma, according to results from a small single-arm trial. The combination achieved an objective response rate (ORR) of 40% in patients who had progressed on or were resistant to prior platinum-pemetrexed … [Read more...]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 23
- Next Page »